Good cop, bad cop: The different faces of NF-κB

Cell Death and Differentiation

Volumn 13, Issue 5, 2006, Pages 759-772

  Perkins, N D ^a   Gilmore, T D ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Boston University   (United States)

Author keywords

Cancer; NF B; Phosphorylation; Post translational modification; Signal transduction; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DAUNORUBICIN; DOXORUBICIN; GLUCOCORTICOID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYPOXIA INDUCIBLE FACTOR 2ALPHA; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P50; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN TUMOR; CANCER; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; COLORECTAL CANCER; COMPLEX FORMATION; CYLINDROMA; DRUG EFFICACY; DRUG TARGETING; ENHANCER REGION; ENZYME ACTIVATION; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

CARCINOGENS; HUMANS; I-KAPPA B KINASE; MODELS, BIOLOGICAL; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33645971047     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401838     Document Type: Review

References (100)

1. Hayden MS and Ghosh S (2004) Signaling to NF-κB. Genes Dev. 18: 2195-2224
2. Bonizzi G and Karin M (2004) The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25: 280-288
3. Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853-6866
4. Kucharczak J, Simmons MJ, Fan YJ and Gelinas C (2003) To be, or not to be: NF-κB is the answer - role of Rel/NF- κB in the regulation of apoptosis. Oncogene 22: 8961-8982
5. Karin M, Yamamoto Y and Wang QM (2004) The IKK NF-κB system: A treasure trove for drug development. Nat. Rev. Drug Discov. 3: 17-26
6. Pande V and Ramos MJ (2005) NF-κB in human disease: Current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem. 12: 357-374
7. Kumar A, Takada Y, Boriek AM and Aggarwal BB (2004) Nuclear factor-κB: its role in health and disease. J. Mol. Med. 82: 434-448
8. Perkins ND (2004) NF-κB: Tumor promoter or suppressor? Trends Cell. Biol. 14: 64-69
9. Perkins ND (1997) Achieving transcriptional specificity with NF-κB. Int. J. Biochem. Cell. Biol. 29: 1433-1448
10. Saccani S, Pantano S and Natoli G (2003) Modulation of NF-κB activity by exchange of dimers. Mol. Cell 11: 1563-1574
11. Viatour P, Merville MP, Bours V and Chariot A (2005) Phosphorylation of NF-κB and IκB proteins: Implications in cancer and inflammation. Trends Biochem. Sci. 30: 43-52
12. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB and White MR (2004) Oscillations in NF-κB signaling control the dynamics of gene expression. Science 306: 704-708
13. Campbell KJ and Perkins ND (2004) Post-translational modification of RelA(p65) NF-κB. Biochem. Soc. Trans. 32: 1087-1089
14. Hoffmann A, Levchenko A, Scott ML and Baltimore D (2002) The IκB-NF-κB signaling module: Temporal control and selective gene activation. Science 298: 1241-1245
15. Hoffmann A, Leung TH and Baltimore D (2003) Genetic analysis of NF-κB/ Rel transcription factors defines functional specificities. EMBO J. 22: 5530-5539
16. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, Jegga AG, Aronow BJ, Ghosh G, Rickert RC and Karin M (2004) Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23: 4202-4210
17. Beinke S, Robinson MJ, Hugunin M and Ley SC (2004) Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105. Mol. Cell. Biol. 24: 9658-9667
18. Kato T, Delhase M, Hoffmann A and Karin M (2003) CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol. Cell 12: 829-839
19. Romieu-Mourez R, Landesman-Bollag E, Seldin DC and Sonenshein GE (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 62: 6770-6778
20. Tergaonkar V, Bottero V, Ikawa M, Li QT and Verma IM (2003) IκB kinase-independent IκBα degradation pathway: Functional NF-κB activity and implications for cancer therapy. Mol. Cell. Biol. 23: 8070-8083
21. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA and Peyron J (1996) Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α. Cell 86: 787-798
22. Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M and Piette J (2000) Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of IκBα in NF-κB activation by an oxidative stress. J. Immunol. 164: 4292-4300
23. Mukhopadhyay A, Manna SK and Aggarwal BB (2000) Pervanadate-induced nuclear factor-κB activation requires tyrosine phosphorylation and degradation of IκBα. Comparison with tumor necrosis factor-α. J. Biol. Chem. 275: 8549-8555
24. Bui NT, Livolsi A, Peyron JF and Prehn JH (2001) Activation of nuclear factor κB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IκBα. J. Cell. Biol. 152: 753-764
25. Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF and Teitelbaum SL (1998) Tumor necrosis factor-α activation of nuclear transcription factor-κB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of IκBα. J. Biol. Chem. 273: 29417-29423
26. Huang TT, Wuerzbrger-Davis SM, Wu ZH and Miyamoto S (2003) Sequential modification of NEMO/IKK gamma by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115: 565-576
27. Bohuslav J, Chen LF, Kwon H, Mu Y and Greene WC (2004) p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279: 26115-26125
28. Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, Kracht M and Schmitz ML (2004) Transient and selective NF-κB p65 serine 536 phosphorylation induced by T cell costimulation is mediated by IκB kinase β and controls the kinetics of p65 nuclear import. J. Immunol. 172: 6336-6344
29. Sasaki CY, Barberi TJ, Ghosh P and Longo DL (2005) Phosphorylation of RelA/p65 on serine 536 defines an IκBα -independent NF-κB pathway. J. Biol. Chem. 280: 34538-34547
30. Lawrence T, Bebien M, Liu GY, Nizet V and Karin M (2005) IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143
31. Saccani S, Marazzi I, Beg AA and Natoli G (2004) Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor κB response. J. Exp. Med. 200: 107-113
32. Hoberg JE, Yeung F and Mayo MW (2004) SMRT derepression by the IκB kinase α: A prerequisite to NF-κB transcription and survival. Mol. Cell 16: 245-255
33. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y and Gaynor RB (2005) Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell 18: 71-82
34. Gringhuis SI, Garcia-Vallejo JJ, van Het Hof B and van Dijk W (2005) Convergent actions of IκB kinase β and protein kinase Cδ modulate mRNA stability through phosphorylation of 14-3-3β complexed with tristetraprolin. Mol. Cell. Biol. 25: 6454-6463
35. Lee S, Andrieu C, Saltel F, Destaing O, Auclair J, Pouchkine V, Michelon J, Salaun B, Kobayashi R, Jurdic P, Kieff ED and Sylla BS (2004) IκB kinase β phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. Proc. Natl. Acad. Sci. USA 101: 17416-17421
36. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R and Hung MC (2004) IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237
37. Zhang JY, Green CL, Tao S and Khavari PA (2004) NF-κB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev. 18: 17-22
38. Hu YL, Baud V, Oga T, Kim KII, Yoshida K and Karin M (2001) IKK α controls formation of the epidermis independently of NF-κB. Nature 410: 710-714
39. Ohazama A, Hu Y, Schmidt-Ullrich R, Cao Y, Scheidereit C, Karin M and Sharpe PT (2004) A dual role for IKK α in tooth development. Dev. Cell 6: 219-227
40. Bracken CP, Whitelaw ML and Peet DJ (2005) Activity of hypoxia-inducible factor 2α is regulated by association with the NF-κB essential modulator. J. Biol. Chem. 280: 14240-14251
41. Madrid LV, Mayo MW, Reuther JY and Baldwin AS (2001) Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276: 18934-18940
42. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU and Brady JN (2005) Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24: 6719-6728
43. Haller D, Russo MP, Sartor RB and Jobin C (2002) IKKβ and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-κB activation in both primary and intestinal epithelial cell lines. J. Biol. Chem. 277: 38168-38178
44. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W and Haegeman G (1998) p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor κB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273: 3285-3290
45. Saccani S, Pantano S and Natoli G (2002) p38-dependent marking of inflammatory genes for increased NF-κB recruitment. Nat. Immunol. 3: 69-75
46. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, Mahadevan LC and Arthur JS (2003) MSK2 and MSK1 mediate the mitogen-and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 22: 2788-2797
47. Hanson JL, Hawke NA, Kashatus D and Baldwin AS (2004) The nuclear factor κB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 64: 7248-7255
48. Gapuzan M-E, Pitoc GA and Gilmore TD (2003) Mutations within a conserved protein kinase A recognition sequence confer temperature-sensitive and partially defective activities onto mouse c-Rel. Biochem. Biophys. Res. Commun. 307: 92-99
49. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S and Lu KP (2003) Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12: 1413-1426
50. Yeh PY, Yeh KH, Chuang SE, Song YC and Cheng AL (2004) Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-κB activation by protein phosphatase 4-mediated NF-κB p65 Thr dephosphorylation. J. Biol. Chem. 279: 26143-26148
51. Rocha S, Garrett MD, Campbell KJ, Schumm K and Perkins ND (2005) Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24: 1157-1169
52. De Bosscher K, Vanden Berghe W and Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: Molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522
53. Campbell KJ, Rocha S and Perkins ND (2004) Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol. Cell 13: 853-865
54. Ho WC, Dickson KM and Barker PA (2005) Nuclear factor-κB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-κB-dependent transcription in cancer cells. Cancer Res. 65: 4273-4281
55. Chen LF and Greene WC (2004) Shaping the nuclear action of NF-κB. Nat. Rev. Mol. Cell. Biol. 5: 392-401
56. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW (2004) Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23: 2369-2380
57. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L and Greene WC (2005) NF-κB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25: 7966-7975
58. Natoli G, Saccani S, Bosisio D and Marazzi I (2005) Interactions of NF-κB with chromatin: The art of being at the right place at the right time. Nat. Immunol. 6: 439-445
59. Merika M and Thanos D (2001) Enhanceosomes. Curr. Opin. Genet. Dev. 11: 205-208
60. Lomvardas S and Thanos D (2001) Nucleosome sliding via TBP DNA binding in vivo. Cell 106: 685-696
61. Krappmann D, Wegener E, Sunami Y, Esen M, Thiel A, Mordmuller B and Scheidereit C (2004) The IκB kinase complex and NF-κB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol. Cell. Biol. 24: 6488-6500
62. Leung TH, Hoffmann A and Baltimore D (2004) One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 118: 453-464
63. Sitcheran R, Cogswell PC and Baldwin Jr AS (2003) NF-κB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev. 17: 2368-2373
64. Cogswell PC, Kashatus DF, Keifer JA, Guttridge DC, Reuther JY, Bristow C, Roy S, Nicholson DW and Baldwin Jr AS (2003) NF-κB and IκBα are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-κB. J. Biol. Chem. 278: 2963-2968
65. Stark LA and Dunlop MG (2005) Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis. Mol. Cell. Biol. 25: 5985-6004
66. Luo JL, Kamata H and Karin M (2005) IKK/NF-κB signaling: Balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115: 2625-2632
67. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296
68. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I (2002) p53 stabilization is decreased upon NFκB activation: A role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503
69. Ryan KM, Ernst MK, Rice NR and Vousden KH (2000) Role of NF-κB in p53-mediated programmed cell death. Nature 404: 892-897
70. Rocha S, Martin AM, Meek DW and Perkins ND (2003) p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23: 4713-4727
71. Rocha S, Campbell KJ and Perkins ND (2003) p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12: 15-25
72. Gapuzan M-ER, Yufit PV and Gilmore TD (2002) Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene 21: 2484-2492
73. Gapuzan M-E, Schmah O, Pollock AD, Hoffmann A and Gilmore TD (2005) Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras. Oncogene 24: 6574-6583
74. Ryan KM, O'Prey J and Vousden KH (2004) Loss of nuclear factor-κB is tumor promoting but does not substitute for loss of p53. Cancer Res. 64: 4415-4418
75. Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF and Mann GJ (2005) Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations. Biochem. Biophys. Res. Commun. 332: 873-879
76. Ghiorzo P, Mantelli M, Gargiulo S, Gramigni C, Pastorino L, Banelli B, Villaggio B, Coccia MC, Sementa AR, Garre C and Bianchi-Scarra G (2004) Inverse correlation between p16INK4A expression and NF-κB activation in melanoma progression. Hum. Pathol. 35: 1029-1037
77. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH and Jain RK (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332
78. Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin Jr AS and Whang YE (2002) PTEN blocks tumor necrosis factor-induced NF-κB-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J. Biol. Chem. 277: 11116-11125
79. Hiscott J, Kwon H and Genin P (2001) Hostile takeovers: Viral appropriation of the NF-κB pathway. J. Clin. Invest. 107: 143-151
80. Deng JO, Miller SA, Wang HY, Xia WY, Wen Y, Zhou BHP, Li Y, Lin SY and Hung MC (2002) β-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell 2: 323-334
81. Deng J, Xia W, Miller SA, Wen Y, Wang HY and Hung MC (2004) Crossregulation of NF-κB by the APC/GSK-3β/β-catenin pathway. Mol. Carcinog. 39: 139-146
82. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG and Baek SH (2005) Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature 434: 921-926
83. Higashitsuji H, Nagao T, Nonoguchi K, Fujii S, Itoh K and Fujita J (2002) A novel protein overexpressed in hepatoma accelerates export of NF-κB from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell 2: 335-346
84. Campbell KJ and Perkins ND (2006) Regulation of NF-κB function. Biochem. Soc. Symp. 73: 165-180
85. Bubici C, Papa S, Pham CG, Zazzeroni F and Franzoso G (2004) NF-κB and JNK: An intricate affair. Cell Cycle 3: 1524-1529
86. Kamata H, Honda S, Maeda S, Chang L, Hirata H and Karin M (2005) Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661
87. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao SY, Lin Q, Kubo Y and Khavari PA (2003) NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643
88. van Hogerlinden M, Rozell BL, Ährlund-Richter L and Toftgård R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res. 59: 3299-3303
89. Lind MH, Rozell B, Wallin RP, van Hogerlinden M, Ljunggren HG, Toftgård R and Sur I (2004) Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition. Proc. Natl. Acad. Sci. USA 101: 4972-4977
90. Zhang JY, Tao S, Kimmel R and Khavari PA (2005) CDK4 regulation by TNFR1 and JNK is required for NF-κB-mediated epidermal growth control. J. Cell. Biol. 168: 561-566
91. Hinata K, Gervin AM, Zhang YJ and Khavari PA (2003) Divergent gene regulation and growth effects by NF-κB in epithelial and mesenchymal cells of human skin. Oncogene 22: 1955-1964
92. Maeda S, Kamata H, Luo JL, Leffert H and Karin M (2005) IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121: 977-990
93. Lawrence T, Gilroy DW, Colville-Nash PR and Willoughby DA (2001) Possible new role for NF-κB in the resolution of inflammation. Nat Med 7: 1291-1297
94. Gadjeva M, Tomczak MF, Zhang M, Wang YY, Dull K, Rogers AB, Erdman SE, Fox JG, Carroll M and Horwitz BH (2004) A role for NF-κB subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. J. Immunol. 173: 5786-5793
95. Cao YX, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV and Karin M (2001) IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107: 763-775
96. Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K and Haase I (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417: 861-866
97. Luedde T, Assmus U, Wustefeld T, Meyer zu Vilsendorf A, Roskams T, Schmidt-Supprian M, Rajewsky K, Brenner DA, Manns MP, Pasparakis M and Trautwein C (2005) Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/ reperfusion injury. J. Clin. Invest. 115: 849-859
98. Wang CY, Cusack Jr JC, Liu R and Baldwin Jr AS (1999) Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5: 412-417
99. Liang M-C, Bardhan S, Porco Jr JA and Gilmore TD (2006) Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity. Biochem. Pharmacol., in press
100. Curry III EA, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M and Sweeney CJ (2004) Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest. New Drugs 22: 299-305